Canada • EN | FR AbbVie Care News Center AbbVie Global Menu Don’t go it alone: Peter’s lessons on life with Inflammatory Bowel Disease (IBD) Learn more November 18, 2021 / Press Release AbbVie announces first provincial reimbursement for VENCLEXTA® (venetoclax) with Obinutuzumab for patients with previously untreated chronic lymphocytic leukemia in Quebec Stories Staying strong when facing a blood cancer diagnosis Stories Taking stock on the state of hepatitis C today Feature Allergan is now part of AbbVie. Our approach to innovation builds on strong science combined with the drive to find solutions where the need is the greatest Our Science Pipeline Advancing medicines with strong clinical performance in areas of great need Focus Areas Driving innovation across oncology, immunology, neuroscience and more Careers Work with us to turn world-class research into life-changing results The people and the breakthroughs that are leading to long-lasting impact Responsibility 7,200+ employees in Western Europe and Canada Passionate about our work, responsible in our actions—we go beyond medicine to improve health care and our communities Community $5.1 billion Invested in research and development in 2018 AbbVie combines advanced science, expertise and passion to solve the world’s most serious health issues and have a remarkable impact on people’s lives Our Company Supplier Information FAQ Contact Us Follow us on Instagram Site Map Privacy Policy Terms of Use Standard Terms and Conditions Cookie Settings Copyright ® 2021 AbbVie Corporation. Canada. Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.